Alvaro Moreno‐Aspitia

Also affiliated with Mayo Clinic in Florida

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial”.

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

British Journal of Cancer(2020)10.1038/s41416-020-0786-x

N/A

1.4DataRank · unranked

40 citations

Noam Pondé, Dominique Agbor‐Tarh, Alvaro Moreno‐Aspitia, Martine Piccart, Florentine Hilbers +11 more

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

European Journal of Cancer(2021)10.1016/j.ejca.2021.01.053

N/A

0.685DataRank · unranked

28 citations

Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman +37 more

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

npj Breast Cancer(2022)10.1038/s41523-022-00430-0

N/A

0.417DataRank · unranked

8 citations

Zhuo Li, Daniel Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner +20 more

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.11.012

N/A

0.413DataRank · unranked

10 citations

Yaohua Ma, Claudia De Angelis, François Richard, Christine Desmedt, Ahmad Awada +7 more

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2024.7015

N/A

0.104DataRank · unranked

1 citations

Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno‐Aspitia +7 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3

N/A

0DataRank · unranked

54 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00452-8

N/A

0DataRank · unranked

13 citations

Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé, Christian Maurer +15 more

Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.522

N/A

0DataRank · unranked

0 citations

Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Lieveke Ameye, Marianne Paesmans, Sarra El-Abed +13 more

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-07159-9

N/A

0DataRank · unranked

2 citations

Marie Kassapian, Véronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni +12 more

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open(2024)10.1016/j.esmoop.2024.103938

N/A

0DataRank · unranked

9 citations

M. Piccart-Gebhart, Shona Fielding, John Townend, D.W. Hillman, M. Colleoni +37 more

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

UNC Libraries(2025)10.17615/kfcn-nf74

N/A

0DataRank · unranked

0 citations

Afshin Mashadi-Hossein, Kathleen Tenner, Lisa A. Carey, Zhuo Li, Heather Ann Brauer +20 more

170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial

Annals of Oncology(2020)10.1016/j.annonc.2020.08.292

N/A

0DataRank · unranked

1 citations

Y. Ma, Claudia De Angelis, François Richard, Christine Desmedt, Ahmad Awada +7 more

Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.529

N/A

0DataRank · unranked

0 citations

Angelica Gil, Yaohua Ma, Zhuo Li, Pooja Advani, Alvaro Moreno‐Aspitia +5 more

Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0641

N/A

0DataRank · unranked

20 citations

Vera J. Suman, Jia Yu, Katelyn Santo, Jason P. Sinnwell, Jodi M. Carter +15 more

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

Breast Cancer Research and Treatment(2021)10.1007/s10549-021-06409-y

N/A

0DataRank · unranked

0 citations

Dominique Agbor‐Tarh, Lissandra Dal Lago, Larissa A. Korde, Florentine Hilbers, Christian Jackisch +9 more